Arbutus Biopharma Corporation (ABUS) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Arbutus Biopharma Corporation (NASDAQ: ABUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $4.21 (-1.64% 1D, market cap $656.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABUS ranks #1004 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABUS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXRX (Lexicon Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M) and IMMX (Immix Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, ABUS leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per ABUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447028), Arbutus Biopharma Corporation generated $14.1M in revenue (+128.2% YoY), -$33.5M in net income, and -$39.6M in free cash flow against $94.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±7.3% realized swing band)
Altman Z-Score 1.34 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ABUS currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.69) and Max Pain ($4.42) forces dealer call-delta covering toward $5.72.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arbutus Biopharma Corporation (ABUS) slipped -1.64% to $4.21, trading at 36% of its 52-week range ($3.5 – $5.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that
The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +128.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABUS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABUS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Arbutus Biopharma Corporation (ABUS) ranks #1004 by composite RQD confidence (18/100, grade E) and #410 by equity capitalization ($656.0M). Within this direct 5-issuer industry benchmark cohort, ABUS leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ABUS at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABUS
ACTIVE
Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -1.64% | $656.0M | Benchmark Subject |
| LXRX Lexicon Pharmaceuticals Inc. | E | 27/100 | — | 96.0% | -31.5% | -4.05% | $658.5M | /lxrx-vs-abus → |
| IMMX Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -3.76% | $661.6M | /immx-vs-abus → |
| ANL Adlai Nortye Group Ltd. | D | 47/100 | — | — | — | -7.10% | $662.0M | /anl-vs-abus → |
| BCAX Bicara Therapeutics Inc. | E | 30/100 | — | — | -35.0% | -6.17% | $643.9M | /bcax-vs-abus → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arbutus Biopharma Corporation (ABUS) reported GAAP revenue of $14.1M (+128.2% vs. FY2024 revenue of $6.2M , and -22.4% cumulative change since FY2023) , GAAP net income of -$33.5M, operating cash flow of -$39.6M, and free cash flow of -$39.6M (+39.1% YoY). On the balance sheet, ABUS closed FY2025 with $94.6M in total assets against $0 in total debt (Altman Z-Score: 1.34, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.1M | -$33.5M | -$39.6M | -$39.6M | $94.6M | — |
| FY2024 (FY) | 2024-12-31 | $6.2M | -$69.9M | -$64.8M | -$65.0M | $131.7M | — |
| FY2023 (FY) | 2023-12-31 | $18.1M | -$72.8M | -$85.9M | -$85.9M | — | — |
As of 2026-11-02, Arbutus Biopharma Corporation (NASDAQ: ABUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $4.21 (-1.64% 1D, market cap $656.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABUS ranks #1004 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABUS carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXRX (Lexicon Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M) and IMMX (Immix Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, ABUS leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per ABUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447028), Arbutus Biopharma Corporation generated $14.1M in revenue (+128.2% YoY), -$33.5M in net income, and -$39.6M in free cash flow against $94.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ABUS last traded at $4.21 (-1.64% on volume of 2,526,205 shares), positioning the stock -10.23% below its 50-day simple moving average ($4.69) and -6.24% below its 200-day simple moving average ($4.49). Across its 52-week range of $3.50 to $5.45, ABUS sits at the 36.4% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($3.90 to $4.52).
Why ABUS Stock slipped -1.64% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ABUS carries an RQD Score of 18 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 2 of 20 (ROIC -35%; FCF yield -6.04%), which is the weakest reading and signals that the business is not currently generating cash returns on invested capital. The Whale 13F Flow pillar scores 5 of 20 (institutional accumulation and options positioning), indicating limited supportive institutional flow in the source data. Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), and Macro Regime Fit scores 3 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 5 of 20 (Altman Z 1.34; Piotroski F 3/9; Debt/Equity 0.5), reflecting financial-distress signals. For a prospective investor, the implication is that the upside case rests on events outside current cash generation, while valuation support from earnings or cash flow is absent in the source data. The rating's verdict is an analytical classification, not a recommendation.
Arbutus Biopharma Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The source data does not describe its products, customers, or revenue model beyond reported financial figures. Reported revenue was $14.1M for FY 2025, per the SEC financials. Market capitalization is $0.7B per the profile, shown as $656.0M in market data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $14.1M | $-38.2M | $-33.5M | N/A | $-39.6M | $18.0M | N/A |
| FY 2024 | $6.2M | $-76.3M | $-69.9M | N/A | $-65.0M | $36.3M | N/A |
| FY 2023 | $18.1M | $-78.1M | $-72.8M | N/A | $-85.9M | N/A | N/A |
Per the SEC financials, the company reported losses in each period shown, with operating margin of -60% and net margin of -60% per market data, and gross margin of 0%. ROIC is -35% per market data. Per the Roarable RQD rating, the Altman Z-Score is 1.34, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash declined from $36.3M to $18.0M between FY 2024 and FY 2025 per the SEC financials.
Per the recent news and catalysts feed, the most prominent items are: a Seeking Alpha report referencing a $230M buyback and Moderna cash, framed as de-risking a potential HBV cure path; a MyChesCo report stating Arbutus retires 23% of shares in a $230 Million buyback; a TradingView weekly recap referencing a Moderna $178M payment and AB-101 Phase 1 results; and a Mugglehead and Stock Titan report that the FDA lifted a clinical hold on AB-101, Arbutus' experimental oral hepatitis B drug. A Benzinga report references the stock trading higher. Catalyst-tagged items are the buyback and Moderna-related items; market-wire items cover the clinical hold lift and the Phase 1 results. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, and sector correlations beyond the stated Health Care sector and Biotechnology industry, are not available in source data. Second-order bottlenecks cannot be identified from the provided sources. Investors should monitor the Moderna payment referenced in news items as a counterparty-revenue dependency, while recognizing the source data does not quantify its share of revenue.
Real-time company headlines, analyst actions, and sector developments for Arbutus Biopharma Corporation (ABUS) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Arbutus Biopharma Corporation (ABUS) market action, institutional positioning, and fundamental catalysts.
Welcome to the ABUS (Arbutus Biopharma Corporation) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ABUS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Arbutus Biopharma Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ABUS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.28 (52-wk range $3.50 - $5.45), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).